Andy Chen
Stock Analyst at Wolfe Research
(3.53)
# 850
Out of 5,142 analysts
44
Total ratings
57.69%
Success rate
22.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $69.91 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $27.20 | +83.82% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $88.43 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $481.01 | +13.93% | 2 | Jan 6, 2026 | |
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $826.25 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $13.16 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $22.47 | - | 1 | Nov 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $329.35 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $42.06 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $67.91 | -27.85% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $18.12 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $72.92 | -24.57% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $61 | $18.68 | +226.55% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.29 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $43.79 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $33.32 | -39.98% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $26.14 | -27.31% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $100.85 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $24.32 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $437.79 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $28.07 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $57.93 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $84.60 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $53.98 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $27.76 | -38.76% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $159.03 | -73.59% | 1 | Feb 15, 2024 |
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $69.91
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $27.20
Upside: +83.82%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $88.43
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $481.01
Upside: +13.93%
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $826.25
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $13.16
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $22.47
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $329.35
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $42.06
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $67.91
Upside: -27.85%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $18.12
Upside: -
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $72.92
Upside: -24.57%
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $18.68
Upside: +226.55%
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $54.29
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $43.79
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $33.32
Upside: -39.98%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $26.14
Upside: -27.31%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $100.85
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $24.32
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $437.79
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $28.07
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $57.93
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $84.60
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $53.98
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $27.76
Upside: -38.76%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $159.03
Upside: -73.59%